載入中
NASDAQHealthcareMedical - Devices
最新資料
US$67.74
+US$2.00 · +3.04%
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
收盤時
US$67.74
+US$2.00 · +3.04%
盤後
US$67.74
US$0.00 · 0.00%
10月12日 下午4:39 ET
盤中時間採用ET。市場資料可能有所延遲。
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
日內區間
目前US$67.74
52週區間
目前US$67.74
盤中時間採用ET。市場資料可能有所延遲。
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
日內區間
目前US$67.74
52週區間
目前US$67.74
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 206.25億 USD | 196.72億 USD | 195.52億 USD | 183.41億 USD | 175.85億 USD |
| 銷貨成本 | 123.78億 USD | 114.67億 USD | 116.3億 USD | 111.62億 USD | 104.11億 USD |
| 毛利 | 82.47億 USD | 82.05億 USD | 79.22億 USD | 71.79億 USD | 71.74億 USD |
| 研究與開發 | 12.6億 USD | 13.11億 USD | 12.05億 USD | 10.26億 USD | 8.16億 USD |
| 銷售、一般及管理費用 | 42.25億 USD | 42.69億 USD | 42.82億 USD | 36.31億 USD | 35.63億 USD |
| 營業費用 | 54.85億 USD | 55.8億 USD | 54.87億 USD | 46.57億 USD | 43.79億 USD |
| 利息收入 | — | — | 2600萬 USD | — | 3400萬 USD |
| 利息支出 | 4.5億 USD | 5.05億 USD | 5.42億 USD | 8600萬 USD | 4000萬 USD |
| 折舊和攤銷 | 5.78億 USD | 5.8億 USD | 6.1億 USD | 6.33億 USD | 6.25億 USD |
| 營業利益 | 27.62億 USD | 26.25億 USD | 24.35億 USD | 25.22億 USD | 27.95億 USD |
| 淨利 | 20.84億 USD | 19.93億 USD | 15.68億 USD | 19.16億 USD | 22.47億 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
年度分割調整後的每股現金分配。
US$0.14
2025年（完整年度）+16.7% 自從 2024
2026年（部分年度）：US$0.105
US$0.12
2,024
US$0.14
2,025
US$0.105
2,026*
* 在現有股息歷史記錄中，該日曆年僅包含部分期間。
| 行動 | 除息日 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股息即將實施 | 2026年10月23日 | US$0.04Quarterly | 2026年10月23日 | 2026年11月13日 |
股息 | 2026年7月24日 | US$0.035Quarterly | 2026年7月24日 | 2026年8月14日 |
股息 | 2026年4月2日 | US$0.035Quarterly | 2026年4月3日 | 2026年5月15日 |
股息 | 2026年1月9日 | US$0.035Quarterly | 2026年1月9日 | 2026年2月13日 |
股息 | 2025年10月24日 | US$0.035Quarterly | 2025年10月24日 | 2025年11月14日 |
股息 | 2025年7月25日 | US$0.035Quarterly | 2025年7月25日 | 2025年8月15日 |
除息 2026年10月23日
US$0.04
Quarterly
2026年10月23日登記 · 支付日 2026年11月13日
除息 2026年7月24日
US$0.035
Quarterly
2026年7月24日登記 · 支付日 2026年8月14日
除息 2026年4月2日
US$0.035
Quarterly
2026年4月3日登記 · 支付日 2026年5月15日
除息 2026年1月9日
US$0.035
Quarterly
2026年1月9日登記 · 支付日 2026年2月13日
除息 2025年10月24日
US$0.035
Quarterly
2025年10月24日登記 · 支付日 2025年11月14日
除息 2025年7月25日
US$0.035
Quarterly
2025年7月25日登記 · 支付日 2025年8月15日
報告持有此股票曝險的交易所交易基金。
State Street SPDR S&P 500 ETF1557.T571.91億0.04%129.43兆 JPY0.09%¥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI10.3億0.04%2.3兆 USD0.03%US$381.57-0.10%
Vanguard S&P 500 ETFVOO8.61億0.05%1.8兆 USD0.03%US$715.15-0.06%
Vanguard Morningstar Mid-Cap ETFVO7.01億0.31%2264億 USD0.03%US$80.92-0.27%
Invesco QQQ Trust, Series 1QQQ6.19億0.12%5060.67億 USD0.18%US$745.99-0.70%
iShares Core S&P 500 ETFIVV3.95億0.04%8964.4億 USD0.03%US$781.44-0.07%
State Street SPDR S&P 500 ETFSPY3.6億0.04%8172億 USD0.09%US$778.07-0.06%
Vanguard Morningstar Value ETFVTV3.1億0.12%2624億 USD0.03%US$221.43+0.38%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Mid-Cap ETFVOInvesco QQQ Trust, Series 1QQQiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
